Having demonstrated the efficacy of the CIRP vaccination platform, we translated this to a human setting, designing different immunogens based on the human HCC antigen GPC3, which is expressed in 80% of HCC tumors [24]. Here, GPC3 is linked to hepatocellular carcinoma.